130 likes | 1.5k Views
. . AIRE: Acute Infarction Ramipril Efficacy study - TRIAL DESIGN -. DesignMulticenter, multinational, randomized, double-blind, placebo-controlledPatients2006 patients, aged >18 years, with evidence of heart failure 3
E N D
1. AIRE: Acute Infarction Ramipril Efficacy study
Purpose
To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart failure after MI
Reference
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:8218.
3. AIRE: Acute Infarction Ramipril Efficacy study- RESULTS -
Significant reduction in all-cause mortality in ramipril group compared with placebo (17 vs. 23%, relative risk reduction 23%, P=0.002)
Reduction in mortality apparent as early as 30 days and consistent across a wide range of subgroups
Fewer patients in ramipril group developed severe/resistant heart failure
No significant reduction in reinfarction or stroke
Drug well tolerated, as defined by withdrawal rate from trial: only marginally higher with ramipril
4. AIRE: Acute Infarction Ramipril Efficacy study- RESULTS continued-
5. AIRE: Acute Infarction Ramipril Efficacy study- RESULTS continued-
6. AIRE: Acute Infarction Ramipril Efficacy study- RESULTS continued-
7. AIRE: Acute Infarction Ramipril Efficacy study - SUMMARY -
In patients with non-severe heart failure after MI, ramipril commenced 310 days after MI and continued for a mean 15-month period:
Significantly reduced all-cause mortality
Conferred benefit independent of age, sex, hypertension, angina or concomitant therapy